Profile data is unavailable for this security.
About the company
Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The Company is focused on the development of therapeutic solutions with worldwide access. The Company works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
- Revenue in EUR (TTM)10.85m
- Net income in EUR-26.42m
- Incorporated2002
- Employees138.00
- LocationMedincell SA3 rue des Freres LumiereJACOU 34830FranceFRA
- Phone+33 467021367
- Websitehttps://www.medincell.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medios AG | 1.81bn | 17.97m | 446.35m | 500.00 | 22.98 | 0.8806 | 11.46 | 0.2466 | 0.7615 | 0.7615 | 76.55 | 19.87 | 2.90 | 27.80 | 13.71 | 3,513,961.00 | 2.88 | 3.40 | 3.46 | 4.07 | 5.99 | 6.05 | 0.9931 | 1.01 | 2.15 | 16.94 | 0.0347 | 0.00 | 10.80 | 40.34 | 2.62 | 34.17 | -7.11 | -- |
| Hunan Warrant Pharmaceutical Co Ltd | 183.95m | 28.21m | 450.30m | 1.16k | 15.96 | 1.99 | -- | 2.45 | 2.37 | 2.37 | 15.44 | 19.01 | 0.6713 | 1.50 | 8.93 | 1,246,491.00 | 9.31 | 11.21 | 11.21 | 14.05 | 64.09 | 69.00 | 13.88 | 13.96 | 3.02 | -- | 0.0252 | 8.05 | 10.84 | 18.50 | 15.60 | 19.02 | 24.49 | -- |
| Chengdu Olymvax Biopharmaceuticals Inc | 63.51m | -1.56m | 451.10m | 471.00 | -- | 3.96 | -- | 7.10 | -0.0303 | -0.0303 | 1.23 | 2.21 | 0.3338 | 0.4197 | 1.08 | 1,061,669.00 | -1.22 | 3.17 | -1.70 | 4.68 | 93.29 | 93.00 | -3.64 | 7.44 | 1.92 | -3.90 | 0.2505 | 9.82 | -9.38 | 45.40 | -33.94 | -- | 56.47 | -- |
| Clinuvel Pharmaceuticals Limited | 52.64m | 18.19m | 452.42m | 16.00 | 25.72 | 4.20 | 24.09 | 8.59 | 0.5825 | 0.5825 | 1.69 | 3.56 | 0.4693 | -0.9514 | 7.35 | -- | 16.21 | 21.25 | 18.57 | 23.55 | 109.28 | -- | 34.54 | 41.84 | 6.43 | 14.53 | 0.006 | 7.44 | 24.27 | 26.14 | 46.58 | 18.27 | 68.74 | 20.11 |
| Medincell SA | 10.85m | -26.42m | 452.66m | 138.00 | -- | -- | -- | 41.73 | -1.02 | -1.02 | 0.4086 | -0.8965 | 0.2605 | -- | 6.81 | -- | -63.46 | -- | -115.15 | -- | 60.43 | -- | -243.58 | -366.40 | -- | -4.29 | 1.69 | -- | -8.67 | 44.33 | 21.78 | -- | -- | -- |
| Theravance Biopharma Inc | 56.64m | -41.23m | 459.06m | 99.00 | -- | 2.43 | -- | 8.10 | -0.861 | -0.861 | 1.19 | 4.22 | 0.1352 | -- | 4.57 | 621,313.10 | -9.84 | -40.51 | -10.39 | -48.50 | -- | -- | -72.78 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Soho Global Health Tbk PT | 485.29m | 24.90m | 473.54m | 2.32k | 19.01 | 3.32 | 16.46 | 0.9758 | 34.71 | 34.71 | 676.37 | 198.99 | 1.77 | 5.67 | 4.97 | 3,617,495,000.00 | 9.06 | 7.97 | 16.53 | 14.37 | 16.24 | 19.39 | 5.13 | 4.65 | 1.26 | -- | 0.006 | -- | 12.45 | 12.43 | 4.10 | 49.70 | 21.21 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Mirova SA (Investment Management)as of 30 Jun 2023 | 2.27m | 7.81% |
| Syquant Capital SASas of 31 Dec 2023 | 728.73k | 2.51% |
| Polar Capital LLPas of 31 May 2024 | 626.02k | 2.15% |
| BFT Investment Managers SAas of 31 May 2024 | 313.16k | 1.08% |
| Saint Olive Gestion SNCas of 30 Apr 2024 | 274.73k | 0.94% |
| Financi�re Arbevel SAas of 31 May 2024 | 203.40k | 0.70% |
| Mandarine Gestion SAas of 29 Feb 2024 | 155.50k | 0.54% |
| SG 29 Haussmann SASUas of 24 Jul 2024 | 139.00k | 0.48% |
| Amundi Asset Management SA (Investment Management)as of 31 May 2024 | 129.17k | 0.44% |
| Soci�t� G�n�rale Gestion SAas of 31 May 2024 | 122.34k | 0.42% |
